Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
Sarclisa is the first anti-CD38 treatment approved in China for patients with…
Names of three International Sports Federations updated in the Olympic Charter
30 January 2025 - The 143rd Session of the International Olympic Committee (IOC) today…
Vincerx Pharma, Inc. Announces Reverse Stock Split
SAN MATEO, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc.…
NCLT Approves Resolution Plan for RITE BUILTEC PRIVATE LIMITED
Resolution achieved in overall 450 Days, ending a 15-Year wait for over…
NCLT Approves Resolution Plan for RITE BUILTEC PRIVATE LIMITED
Resolution achieved in overall 450 Days, ending a 15-Year wait for over…
NCLT Approves Resolution Plan for RITE BUILTEC PRIVATE LIMITED
Resolution achieved in overall 450 Days, ending a 15-Year wait for over…
NCLT Approves Resolution Plan for RITE BUILTEC PRIVATE LIMITED
Resolution achieved in overall 450 Days, ending a 15-Year wait for over…
NCLT Approves Resolution Plan for RITE BUILTEC PRIVATE LIMITED
Resolution achieved in overall 450 Days, ending a 15-Year wait for over…
NCLT Approves Resolution Plan for RITE BUILTEC PRIVATE LIMITED
Resolution achieved in overall 450 Days, ending a 15-Year wait for over…
NCLT Approves Resolution Plan for RITE BUILTEC PRIVATE LIMITED
Resolution achieved in overall 450 Days, ending a 15-Year wait for over…